Menu Search
Equities

Molecure SA

1B1:MUN

Molecure SA

Actions
  • Price (EUR)3.59
  • Today's Change0.00 / 0.00%
  • Shares traded-1.00
  • 1 Year change-21.10%
  • Beta--
Data delayed at least 15 minutes, as of May 31 2024 07:15 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Oncoarendi Therapeutics SA is a Poland-based biopharmaceutical company . The Company is dedicated to discovering, developing and commercializing therapeutics for neoplastic and inflammatory diseases. The Company's business model is focused on drug discovery and development, with its core strength in medicinal chemistry and preclinical biology, enhanced by scientific collaborations in specific disease areas. The Company has a platform of 3 distinct small molecule programs targeting chitinases hydrolytic enzymes with potential utility in diverse inflammatory and fibrotic diseases of high unmet medical need. Additionally, it has initiated a program focused on development of small molecule immune modulators to stop the ability of tumors to escape immune surveillance.

  • Revenue in PLN (TTM)1.31m
  • Net income in PLN-18.31m
  • Incorporated2017
  • Employees111.00
  • Location
    Molecure SAZwirki I Wigury 101WARSZAWA 02-089PolandPOL
  • Phone+48 225526724
  • Websitehttps://molecure.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.